SCHEMBL21588079

SCHEMBL21588079

COC(=O)c1ccc(O)c(OCc2ccccc2)c1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.68
LMNA P02545 2/20 0.68
SMPD1 P17405 2/20 0.56
HDAC1 Q13547 1/20 0.56
HDAC8 Q9BY41 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
SMN1; SMN2 Q16637 3/20 0.54
RAB9A P51151 2/20 0.54
NPC1 O15118 1/20 0.54
CA12 O43570 1/20 0.53
CA1 P00915 1/20 0.53
CA2 P00918 1/20 0.53
CA7 P43166 1/20 0.53
XDH P47989 1/20 0.53
CA9 Q16790 1/20 0.53
CA14 Q9ULX7 1/20 0.53
MAPT P10636 2/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
CYP1A2 P05177 1/20 0.52
CYP3A4 P08684 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1782909 0.89 HPGD (0.72) HPGDLMNASMPD1HDAC1HDAC8
SCHEMBL3245222 0.88 SMPD1 (0.67) HPGDLMNASMPD1HDAC1HDAC8
SCHEMBL22015271 0.87 LMNA (0.62) HPGDLMNASMPD1HDAC1HDAC8
SCHEMBL30102539 0.86 LMNA (0.76) HPGDLMNASMPD1HDAC1HDAC8
SCHEMBL2063068 0.86 SMN1; SMN2 (0.73) HPGDLMNASMPD1HDAC1HDAC8
SCHEMBL31241237 0.86 LMNA (0.59) HPGDLMNASMPD1HDAC1HDAC8
SCHEMBL4874871 0.86 LMNA (0.76) HPGDLMNASMPD1HDAC1HDAC8
SCHEMBL16929834 0.86 LMNA (0.59) HPGDLMNASMPD1HDAC1HDAC8
SCHEMBL2188210 0.86 SMPD1 (0.76) HPGDLMNASMPD1HDAC1HDAC8
SCHEMBL30809647 0.85 LMNA (0.64) HPGDLMNASMPD1HDAC1HDAC8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11643405-B2 Compound for treatment or prevention of liver diseases JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-05-09 US disclosed
US-11643405-B2 Compound for treatment or prevention of liver diseases JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2023-05-09 US disclosed
US-20220009892-A1 SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF INCILIA THERAPEUTICS PRIVATE LIMITED (IN) 2022-01-13 US disclosed
US-20210246126-A1 COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2021-08-12 US disclosed
US-20210246126-A1 COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES JIANGSU ATOM BIOSCIENCE AND PHARMACEUTICAL CO., LTD. (CN) 2021-08-12 US disclosed
EP-3805216-A1 COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) 2021-04-14 EP disclosed
EP-3805216-A1 COMPOUNDS FOR TREATMENT OR PREVENTION OF LIVER DISEASES Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd. (CN) 2021-04-14 EP disclosed
WO-2019233440-A1 COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES 江苏新元素医药科技有限公司 (CN) 2019-12-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210246126-A1 COMPOUND FOR TREATMENT OR PREVENTION OF LIVER DISEASES SLC10A1, GYS2, CPT1A HPGD 254/4885LMNA 995/4885SMPD1 1078/4885
US-20220009892-A1 SUBSTITUTED PYRIDINE CARBOXYLIC ACIDS, THEIR PREPARATION METHOD AND COMPOSITIONS THEREOF PC, PCCA, GLS2 HPGD 421/4885LMNA 3457/4885SMPD1 1068/4885
US-11643405-B2 Compound for treatment or prevention of liver diseases SLC10A1, GYS2, CPT1A HPGD 254/4885LMNA 995/4885SMPD1 1078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.